A pharmaceutical company from Singapore has developed a new oral drug for Alzheimer’s disease. The results of its phase III clinical trial are positive, which can slow down the decline in cognitive function and brain atrophy in patients. Therapeutic drugs, among which the Taiwanese factory Xufu (4119-TW) is the exclusive raw material drug supplier of this new drug, which will help Xufu’s operation to accelerate growth and get rid of the decline in recent years.
Xu Fu said that a client developing a new drug for Alzheimer’s disease is expected to apply for a drug license next year, and its factories will also be inspected and certified at the same time. As the client is optimistic compensation for sales, expected to accelerate the company’s operations to return to pre-disaster levels.
According to the results of phase III clinical trials of new oral drugs for Alzheimer’s disease published by TauRx Pharmaceuticals, a pharmaceutical company from Singapore, after early patients received drug treatment, their cognitive ability and brain atrophy continued to improve; compared to patients who had not used drugs in the past, mild to moderate drug-treated patients had more stable cognitive function and less brain atrophy.
With the positive results of clinical trials of new drugs, the company has recently raised US$119 million, and will apply for drug licenses to the competent authorities in the United States, Canada, and the United Kingdom, and will presented the results of the research at the Alzheimer’s Disease Center in San Francisco, USA, which will appear for the first time at the end of this month at the Clinical Trials in Disease (CTAD) Conference.
Xu Fu expects that the production capacity will gradually improve after the fire haze is cleared. With the continuous load of the existing product lines, the operation will return to the pre-disaster level in the second half of next year .In the future, it will be produced in the new Guanyin factory, which will drive a significant jump in revenue.
Alzheimer’s disease is a neurodegenerative disease of the brain and a form of dementia. The development of the disease is irreversible and will not cause immediate death. Most patients die from other complications. According to statistics, there are about 35 million Alzheimer’s patients in the world, of which more than 6 million are in the United States. In 2050, there will be 13 million people, and the business opportunity for drug treatment is as high as 300 billion US dollars.
In fact, the arrival of new drugs for Alzheimer’s disease in the United States dates back to 2003. At that time, the annual revenue of the two approved drugs was about 1.5 billion US dollars, but the new drug could only relieve the symptoms caused by Alzheimer’s disease can not slow down the disease, so many international pharmaceutical companies have invested in the development in recent years, including the development of Japan Weicai and the United States Biogen, Roche Pharmaceuticals, etc.